Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Lymphoma International Prognostic Index (CLIP-B) for Advanced-Stage Cutaneous T-Cell Lymphoma
Description
The speaker explains the development and clinical value of the Cutaneous Lymphoma International Prognostic Index for advanced-stage cutaneous T-cell lymphoma (CLIP-B). Because standard clinical staging does not fully capture prognosis, an international group first analyzed retrospective advanced-stage cases, then validated the model prospectively through a large multicenter effort. The final CLIP-B identifies four key adverse factors: older age, extracutaneous disease, large-cell transformation, and elevated LDH; in the prospective cohort, nodal status—especially biopsy-proven N3 disease—was particularly important, while blood burden was not independently prognostic. These factors separate patients into low-, intermediate-, and high-risk groups with clearly different survival, with high-risk patients having poor five-year outcomes and often needing consideration for allogeneic transplant. The talk emphasizes how CLIP-B can help guide treatment decisions, especially transplant referral, and can improve clinical trial stratification. It also notes areas still needing work, including refinement of early-stage prognostic tools, validation in additional populations, and incorporation of molecular, biologic, quality-of-life, and AI-based prognostic factors.
View moreConclusions
- Advanced stage CTCL prognosis can be improved beyond clinical staging by using the CLIPI risk model.
- In advanced MF/SS, the strongest adverse prognostic factors are older age, N3 nodal disease, elevated LDH, and skin large-cell transformation.
- Advanced-stage patients can be separated into clearly distinct low-, intermediate-, and high-risk survival groups using CLIPI.
- Blood tumor burden was not a significant independent prognostic factor in the validated advanced-stage cohorts, despite prior suspicion that it might be.
- Nodal disease, especially biopsy-proven N3 involvement, appears to be a critical driver of poor outcome and treatment escalation.
- CLIPI may help identify patients who should be considered for allogeneic HSCT, particularly those with high-risk disease and selected intermediate-risk patients.
- Even some patients with initially low-risk CLIPI can later become transplant candidates if their disease becomes refractory or biologically worse.
- Current staging systems remain useful but do not fully capture important biologic and burden-related differences within stages.
- Early-stage prognostic modeling is still incomplete, but features such as widespread plaques, confluent erythema, and LCT may prove important.
- Further validation in additional cohorts, incorporation of molecular and quality-of-life variables, and development of subpopulation-specific indices are needed to refine prognostication in CTCL.
- Agar et al. J Clin Oncol 2010.
- PROCLIPI Study, Scarisbrick et al. Blood 2025.
- Goyal et al. JAAD 2025.